Back to press releases
MARLBOROUGH, MA, October 12, 2005 – Optos Inc., a leader in ophthalmic retinal imaging, will host several key educational initiatives surrounding the optomap® Retinal Imaging Platform at the American Academy of Ophthalmology in Chicago, IL from October 15 – 18.
Carmen Puliafito, MD, MBA, will host and moderate a free CME breakfast seminar, “Widefield Angiography: a New Tool for the Management of Retinal Vascular Disease and Intraocular Tumors.” Joining him are distinguished faculty members Thomas S. Friberg, MD, Steve Schwartz, MD, and Roger Novack, MD. They will discuss the application of ultra-widefield angiography in early disease diagnosis, the management of diabetic retinopathy and other forms of retinal pathology including vascular disease, tumors and macular degeneration.
The Optos Academy, created and launched to enable Optos partners to attain a high level of success with the optomap® Retinal Exam, will also be featured during the American Academy of Ophthalmology on Sunday, October 16. Speakers include Donald Digby, MD who will introduce and explore the capabilities of Optos’ new product, the optomap® plus Medical Retinal Exam and Alastair Atkinson, Optos Global Product Director, who will outline optomap® fa, Optos’ forthcoming fluorescein angiography product. The Academy will also highlight internal and external marketing strategies that practitioners can utilize to improve patient acceptance levels. Forthcoming clinical and software updates will also be introduced at the Academy.
Throughout the conference, Optos will host various “Meet the Experts” forums in its booth, #2507. Featured presentations include:
- Calvin W. Roberts, MD – The Value of the optomap® Retinal Exam to the Anterior Segment Surgeon
- Donald Digby, MD – Using optomap® and optomap® plus for Glaucoma Detection and Management
- Thomas S. Friberg, MD – Detection of Capillary Drop Out in Ultra-widefield Angiography in Patients with Clinically Significant Diabetic Macular Edema
- Ivan Suner, MD – optomap® fa – New Developments in Ultra-Widefield Angiography
- Donald Serafano, MD – The optomap® Retinal Exam in a Comprehensive Ophthalmic Practice
- Carmen Puliafito, MD, MBA – The Optos Retinal imaging Platform – the Evolution of the Modern Retinal Exam
- Steven Schwartz, MD – Peripheral Angiographic Evaluation of Vitreoretinal Disease Using optomap® fa
Since the optomap® Retinal Exam’s inception in 1999, almost 5 million exams have been conducted world wide, aiding in the detection and diagnosis of serious eye conditions such as diabetic retinopathy, retinal detachments, macular degeneration, and other sight or life threatening pathologies such as melanomas, hypertension and diabetes.
Optos is a leading provider of innovative solutions for comprehensive retinal evaluation, enabling practitioners to more effectively detect, monitor and promote patient health. The optomap® Retinal Exam is an integral first step in the clinical evaluation of every patient annually. It non-invasively generates an instantaneous, ultra-widefield digital scan of the retina, revealing important information for the comprehensive evaluation of systemic and ocular health. More than 1,900 practices across North America are currently offering the optomap® Retinal Exam and carry out more than 10,000 optomap® images daily.
The optomap® plus Medical Retinal Exam enables practitioners to document that a specific capture and review process has been followed. This can then be used to support reimbursement claims, as required. The Optomap Plus Medical Retinal Exam is complementary to the Optomap Retinal Exam for patients diagnosed with or presenting pathology.
optomap® fa provides dynamic ultra-widefield angiography, enabling a simultaneous pole to periphery view of the retina for enhanced disease detection and treatment determination. The dynamic optomap® fa angiographic studies enable practitioners to diagnose ocular pathology that may first present in the periphery of the retina. Ultra wide-field angiography has FDA approval to market.
Optos North America (www.Optos.com), the wholly-owned subsidiary of Optos plc, is headquartered in Marlborough, MA. Optos plc and the company's development center are located in Dunfermline, Scotland.